UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

TTX-030 is the first fully human IgG4 antibody designed to target CD39, as well as the first CD39 inhibitor to undergo a phase 1 clinical trial.

Oncology nurses must assess the total pain of their patients by considering the physical, psychological, social, emotional, and spiritual elements.

As prognoses continue to improve, concerns about treatment-associated fertility risks are becoming more prevalent and are often a topic of discussion between patients and their nurses or nurse practitioners.

Lindsay Kroener, MD, offers an overview of current fertility preservation options for patients about to undergo cancer therapy.

At a presentation during the 39th Annual Miami Breast Cancer Conference, Lindsay Kroener, MD, highlighted key components related to fertility preservation for patients with breast cancer.

The nurse-specific track returns to the Miami Breast Cancer Conference® agenda for a second year in 2022.

Awareness of the e-cigarette epidemic among youth could help drive primary prevention.

An expert from the University of California Los Angeles (UCLA) discusses the alarming rate of high-risk uterine cancers among Black women and how researchers are investigating the underlying risk factors at play.

A newly designed model will outline what genetic patterns put men with prostate cancer at an increased risk of toxic side effects.

Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.

In this episode of “The Vitals,” 2 veteran oncology nurses discuss the value of mentorship—particularly for novice nurses.

An expert discusses the implications of a subgroup analysis of the DESTINY-BREAST03 trial, which highlighted the efficacy of trastuzumab deruxtecan in HER2-positive metastatic breast cancer.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, discusses the importance of NCCN guidelines in prescribing medications for patients with chronic leukemia. .

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, discusses omacetaxine as a novel regimen in CML treatment.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on how health care providers can effectively care for patients with COVID-19 and hematologic malignancies.

As health care providers and essential workers, we remain the most trusted profession. We, therefore, have a responsibility to our patients to be examples that influence vaccination decisions.

Combining immunotherapy with other targeted therapies may result in more promising outcomes than immunotherapy alone in the treatment of recurrent ovarian cancer, according to an expert at University of California, Los Angeles.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on the dedication she has observed from caregivers taking care of loved ones with leukemia during the COVID-19 era.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News Co-Editor in Chief, shares her opinion on recent developments in leukemia treatment options.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses her recent School of Nursing Oncology presentation.

Multidisciplinary approaches are still needed to proactively address the high relapse rates in patients with ovarian cancer treated with platinum-based chemotherapies, says Sanaz Memarzadeh, MD, PhD.

Psychological support services for patients and colleagues are critically needed and should be a vital component in postpandemic planning. 

“If you're an oncology nurse, you will have patients with immunotherapy–which is why we want to make sure that we are really familiar with these side effects.”

With a newfound abundance of available oral cancer therapies, it has become necessary for oncology nurses to ensure that their patients are adhering to treatment.

While PARP inhibitors have played a large part in improving progression-free survival (PFS) in patients with ovarian cancer, long-term use of these agents often leads to resistance that are often quite challenging to overcome, according to Gottfried E. Konecny, MD.

Despite many exciting advances in recent years, there are still aspects of melanoma treatment that need to be further studied and understood, said Grace Cherry, NP, a nurse practitioner at UCLA Health.

“Nurses are our frontline as far as giving these treatments and also in teaching our patients about side effects and detecting them,” Grace Cherry, NP, MSN, RN said.

Palliative care providers must, “lean into patient care in creative ways.”

The recent FDA approval of sacituzumab govitecan for certain patients with triple-negative breast cancer was an exciting one. Here’s what oncology nurses need to know.